Orthocell (ASX:OCC) has taken an important step in its international expansion plans, submitting a regulatory application to the British Standards Institution seeking approval to commercially distribute its nerve repair device, Remplir, across the European Union and the United Kingdom.
Orthocell lodges European and UK regulatory application for Remplir
December 15, 2025 Australian Biotech
Latest Video
New Stories
-
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News -
The leadership challenge behind Australia’s medicine access gap
March 13, 2026 - - Latest News -
Australia has spent four decades having the wrong conversation about medicines access
March 13, 2026 - - Latest News -
‘An absolute medical miracle’ - MPs highlight progress and challenges at Cystic Fibrosis event
March 13, 2026 - - Latest News -
Australia’s top community pharmacists honoured at national awards
March 13, 2026 - - Latest News -
A new prostate cancer technology moves closer to global trials after strong early results
March 12, 2026 - - Australian Biotech

